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The Roslin Institute
What is it famous for?  Dolly the
sheep, who in February this year,
made headlines as the first mammal
to be cloned from a somatic cell
derived from an adult animal. The
publication of this work by Roslin
Institute researchers sparked
intense media speculation about
human cloning.
Was Dolly the first to make a splash?
No. Media attention had already
been caught in 1991 with Tracy the
sheep, the first transgenic farm
animal capable of secreting a human
protein in its milk. To commercialize
the use of the mammary gland as a
‘biofactory’ for producing medically
important proteins, a company PPL
Therapeutics was established. When
floated on the London stock
exchange in June 1996, PPL shares
were valued at £110 million. 
Is PPL closely associated with the
Institute?  Surprisingly, The Roslin
does not own shares in PPL. They
do collaborate on projects, and Keith
Campbell — widely accredited with
refining the nuclear transfer
technology that produced Dolly —
has now left The Roslin to join PPL.
Are there other research interests
there?  The Roslin has 300 staff and
students and its declared mission is
to improve the productivity,
breeding and welfare of farm
animals. Although not the stuff of
high-profile science, there is a
nonetheless laudable programme of
research into bone disorders in
broiler chickens and management of
stress in poultry. Poultry and
livestock genome mapping is
another area of specialization. The
Roslin coordinates a Europe-wide
project that has produced a linkage
and physical map of the pig
genome. To exploit intellectual
property arising from its genome
analysis program, and to provide a
commercial genotyping service, a
second company — Roslin
Genotyping Services — was
established in late 1996.
How is the institute funded?  It was
owned by the UK Biotechnology
and Biological Sciences Research
Council (BBSRC) until April 1995,
when it became a non-profit
company registered as a charity.
About 20% of its annual research
income (£7.7 million in 1996) still
comes from the BBSRC in the form
of a block grant. This is expected to
change, and The Roslin will
compete for BBSRC funding and
undergo a research assessment
exercise similar to that conducted for
UK universities. Additional support
is provided by the European Union,
the UK Ministry of Agriculture,
Fisheries and Food (MAFF) and
industry. Recently, MAFF withdrew
its support for a number of research
programs leading to immediate
redundancies. Three project leaders
in the animal welfare research
division lost their jobs.
Where is it located?  In Scotland, 7
miles south of Edinburgh, on a 36-
acre site that it shares with PPL.
Most labs have vistas of grazing
sheep and of the Pentland Hills.
There are ambitious plans to
develop the site as a biotech park
with an additional 8500 m2 of lab
space for new companies. The
Institue borrows its name from the
nearby village of Roslin which is
renowned for its 15th century
Gothic chapel.
What’s it like to work there?  The
atmosphere is congenial and
deceptively laid back. Most people
seem unperturbed by the occasional
threats of exploding mail. Lunchtime
conversation is as likely to be about
genome mapping as about the
number of Munros (a Scottish term
for a hill over 3000 feet) one has
‘bagged’ over the weekend.
Introns
No comment
“The Royal Academy of Sciences in
Stockholm took the unusual step of
splitting the Chemistry award. Half
went to Jens Skou from Denmark,
and the remainder was split between
John Walker and Paul Boyer.
“ . . . Mr Boyer and Mr Walker
received the award for their work on
how the enzyme ATP Synthase uses
energy to recreate itself.
“ . . . Mr Walker and his team
found that a running down of the
mechanism of ATP Synthase could
play a key role in diseases related to
ageing.”
The Independent (UK) 16 October 1997.
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The recent Correspondence from
Sonnhammer and Wootton [1]
regarding a new family of eukaryotic
proteins similar to bacterial DNA
polymerase I raises a number of
interesting questions. Our report on
the characterization of the Drosophila
DNA repair gene mus308 [2] and a
related Caenorhabditis elegans gene
addresses several of these questions,
including the possible role of this
gene family. 
The mus308 gene (Genbank
L76559) encodes a 229 kDa
polypeptide, the carboxy-terminal
domain of which is closely related to
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the polymerase domain of the
bacterial DNA polymerase I
enzymes. Remarkably, the amino-
terminal domain of the Mus308
polypeptide also includes the seven
amino-acid sequence motifs that are
characteristic of the ‘superfamily 2’
DNA and RNA helicases [3]. This
finding makes mus308 not only the
first characterized gene encoding a
eukaryotic homolog of the bacterial
DNA polymerase I family, but also
the first reported gene encoding both
helicase and polymerase motifs in a
single polypeptide.
A gene very similar to mus308,
which we have designated mus-1,
encoded by genomic sequences in
the cosmids R12B2 (U00066) and
W03A3 (U50184), is predicted to
exist in C. elegans. A combination of
genomic and partial cDNA
sequences indicate that the carboxy-
terminal domain of the Mus-1
polypeptide is highly homologous to
the polymerase domains of Mus308
and other members of the DNA
polymerase I family [2], as noted by
Sonnhammer and Wootton [1]. Upon
comparing the remainder of the
mus308 coding sequences and C.
elegans genomic sequences located
upstream of the Mus-1 polymerase
domain, a helicase domain closely
related to the Mus308 helicase
domain was immediately apparent
[2]. Further limited sequence
homology between the Mus308 and
predicted Mus-1 polypeptides was
also seen in the region between the
helicase and polymerase domains
(P.H., unpublished observations).
The juxtaposition of Mus308-related
helicase and polymerase domains
and sequence similarities in the
region between the two domains
strongly support the hypothesis that
the mus-1 gene encodes a protein
homologous to Mus308. The
existence of an evolutionarily
conserved enzyme family with this
unique combination of helicase and
polymerase motifs suggests a
conserved functional role in DNA
repair for these proteins. Direct
evidence for such a role is available,
however, only for Mus308 [4], which
is required to repair the damage
caused by mutagens such as nitrogen
mustard and cisplatin that result in
interstrand cross-links [5].
As reported by Sonnhammer and
Wootton [1], two distinct human
sequences encoding polypeptides
with similarity to the polymerase
domain of the bacterial DNA
polymerase I family are also present
in the sequence databases. We have
also noted the existence of these
coding sequences, which encode
polypeptides related to the Mus308
polymerase domain. The sequence
most closely related to mus308 is
represented by human cDNA clone
za38h12.r1 (Genbank W00829).
Sequence information from partial
cDNAs and RT-PCR products
derived from this gene show
additional homology to mus308 in
sequences upstream of the
polymerase domain (P.V.H. and
K.C.B., unpublished observations),
suggesting homology to the
mus308/mus-1 family; however, the
presence of helicase motifs remains
to be established. We have also noted
the sequences homologous to the
Mus308 polymerase domain in the
Huntington’s disease region of the
genome, as reported by Sonnhammer
and Wootton [1]. In this case,
however, the availability of almost
2 megabases of sequence information
upstream of this domain reveals the
absence of any recognizable helicase
motifs (P.V.H. and K.C.B.,
unpublished observations),
suggesting that this gene is not likely
to be a functional homolog of the
mus308/mus-1 family. 
Sonnhammer and Wootton [1]
note that it is ‘tempting to consider
DNA repair’ as a possible function of
these DNA polymerases, but that
‘experimental verification of
polymerase activity is the next step.’
Our previous report [2] indeed
confirms a role in DNA repair for at
least the prototypical member of this
new gene family, mus308.
Furthermore, we have recently
determined that the polymerase
domain of the polypeptide encoded
by the za38h12.r1 human cDNA
possesses enzymatic polymerase
activity, confirming the prediction
based on amino-acid sequence
(P.V.H. and K.C.B., unpublished
observations). In the light of this
enzymatic activity, we have termed
this new human DNA polymerase
gene POLH. The next step is to
determine the functional role of the
polymerase (and possibly helicase)
domains of this new class of
eukaryotic DNA polymerases in
DNA repair and other cellular
functions.
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